Objectives: Bacterial drug resistance is a worrying public health problem and there is an urgent need for research and development to provide new antibacterial molecules. Peptide deformylase (PDF) is now a welldescribed intracellular target selected for the design of a new antibiotic group, PDF inhibitors (PDFIs). The initial bacterial susceptibility to an inhibitor of a cytoplasmic target is directly associated with the diffusion of the compound through the membrane barrier of Gram-negative bacteria and with its cytosolic accumulation at the required concentration.
Introduction
Protein synthesis in both prokaryotic and eukaryotic cells is typically initiated by ribosomal binding to a formyl methioninecharged transfer RNA (tRNA fMet ). As a result, all N-terminal peptides start systematically with a formyl methionine. 1 Nevertheless, .99% of mature proteins do not retain the formyl group and among them more than one-half undergo removal of their methionine before protein synthesis is achieved. 2 Indeed, most proteins undergo very early processing by deformylation of the N-terminal methionine through the action of peptide deformylase (PDF) followed by the excision of the resulting methionine by methionine aminopeptidase (METAP). 3, 4 Because this cotranslational process has been shown to be essential to bacteria, PDF has been the recent focus of intense studies as an attractive and original antibacterial target against resistant bacteria. 5, 6 Actinonin (Act), a naturally occurring antibiotic isolated from the Gram-positive actinobacterium Streptomyces roseopallidus, was shown to specifically and very potently (i.e. in the low nanomolar range) target bacterial PDFs. 7 This efficiency is associated with a conformational change of the target resulting in an increase in the stability of the enzyme/ligand. 8, 9 Since then, new series of peptide and nonpeptide inhibitors have been designed and tested both in vitro on purified enzymes and in living bacteria. 5,6,10 -22 Most of them, although potent PDF inhibitors in vitro, showed variable antibacterial activities against Gram-positive bacteria and limited activities against Gram-negative bacteria such as Escherichia coli, Enterobacteriaceae or Pseudomonas aeruginosa. 6 This limited potency against Gram-negative bacteria is due to the presence of a strong low-permeability barrier of the outer membrane organization combined with an active efflux, which affects susceptibility to a very broad range of different compounds, including antibiotics, biocides, dyes and detergents. 23, 24 Moreover, the level of expression of efflux pumps, e.g. AcrAB-TolC, in various clinical multidrug-resistant isolates has been shown to contribute to decreases in the activity of various different PDF inhibitors (PDFIs). 25, 26 Thus, taking into account the lower levels of activity against both Gram-negative and Gram-positive species, chemosensitizers and/or efflux pump inhibitors have been employed to obtain significant activity of PDFIs in living bacteria and also against resistant bacterial strains. 26 -28 In addition to the mechanical barrier, 23 bacterial pathogens have developed other resistance mechanisms against PDF inhibitors, including: (i) bypassing the requirement for PDF activity by circumventing the initial formylation step (where this mechanism of resistance only applies to those bacteria that remain viable in the absence of a formylation/deformylation cycle); 29, 30 and (ii) overexpressing PDF to saturate the PDFIs (for a review see Leeds and Dean 31 ). In order to bypass the bacterial mechanical barrier against PDF inhibitors, we have previously developed the use of permeabilizers, which improve the diffusion of the molecules through the membrane and increase the internal accumulation of the antibacterial molecules (for a review see Bolla et al. 27 ). In our search for new antibacterial agents, we completed our series of inhibitors with an indole as a non-peptide scaffold 11, 32 with compounds containing an oxadiazole as an isostere of amide functions. For this study we selected two new lead compounds, AT002 and AT008, and two previously reported indole derivatives, AB47 and SMP289. We show a significant increase in antibacterial activity when some of these inhibitors are used in combination. This increased potency with the combination of two PDFIs has been further correlated with the capacity of both ligands to interact simultaneously or not with the PDF, or the capacity of one ligand to interact with METAP.
NMR experiments suggest that previous binding of Act to PDF impairs any further interaction of the enzyme with AT002 or AT008. Binding of Act to PDF does not alter the binding affinity of SMP289 to the enzyme, whereas association of the enzyme with SMP289 decreases the affinity of both AT002 and AT008. Taken together, these results suggest that antibacterial activities can be improved by combining two compounds of these series together or by combining one compound with Act. This new strategy could be used for the development of new antibiotics.
Materials and methods

Bacterial strains
The various strains are presented in Table 1 . Briefly, Escherichia coli K-12 AG100 [argE3 thi-1 rpsL xyl mtl delta (gal-uvrB) supE44] and AG100A (acrAB2) have been characterized previously. 28 Pseudomonas aeruginosa strains were PA01 (ATCC) and the clinical isolate PA124. Enterobacter aerogenes Ea289, and Ea294 (acrA2) and Ea298 (tolC2) derivatives, have been described previously. 28 
Chemicals
Act was purchased from Sigma-Aldrich. Syntheses of AB47 and SMP289 were previously reported 11, 33 and those of AT002, AT008 and A023 are described in the Supplementary data (available at JAC Online). All the products are shown in Table 2 . Norfloxacin and chloramphenicol were used as reference antibiotics. Polymyxin B nonapeptide (PMBN), a cationic peptide that perturbs the outer membrane bilayer, was used as a permeabilizing agent as previously described. 28 
Antibiotic susceptibility assays
Bacteria were grown in Mueller-Hinton (MH) broth at 378C. Susceptibilities to antibiotic compounds (polymyxin B, PMBN, norfloxacin and chloramphenicol) were determined by the broth dilution method as previously described. 28 MICs were determined with an inoculum of 10 6 cfu in 1 mL of MH broth containing 2-fold serial dilutions of each antibiotic. Isolates were classified as susceptible, intermediately susceptible or resistant to the antibiotics tested according to the Antibiogram Committee of the French Society for Microbiology. 34 For combination assays, serial dilutions of tested molecules were incubated in the presence of PMBN at 1/10 or 1/5 MICs as previously determined. 28 Norfloxacin and chloramphenicol, belonging to unrelated structural antibiotic groups, were used as internal standards. The results were scored after 18 h at 378C and were expressed as mg/L (MIC).
Purification of the apo-enzyme apo-EcMETAP
The expression plasmid for EcMETAP (pET28b-EcMETAP) was a gift from Professor J. Larrabee, Dr W. T. Lowther and Professor B. W. Matthews (Institute of Molecular Biology, Howard Hughes Medical Institute and Department of Physics, University of Oregon, Eugene, USA). 33 EcMETAP was purified as the apo-enzyme using the previously described protocol of Lowther et al. 33 with some minor modifications, described as follows. BL21(DE3) E. coli cells transformed with the expression plasmid pET28b-EcMETAP(R175Q) were grown in Luria-Bertani broth containing kanamycin (30 mg/L) at 378C until OD 600 reached 0.5-0.7. Expression was then induced by addition of 0.5 mM isopropyl b-D-thiogalactoside Active combination of PDF-METAP inhibitors 1393 JAC for 3 h at 258C. The cell pellets were lysed for 30 min at 48C in lysis buffer +T/G (Tris/glycine) containing 50 mM HEPES pH 7.9, 0.5 M KCl, 10% glycerol, 15 mM methionine, 40 mg/mL DNase, 0.25 mg/mL lysozyme and Novagen Bugbuster 1×, and then centrifuged at 40 000 g for 45 min.
The supernatant was incubated in batches for 1 h at 48C with His-select Nickel affinity gel (Sigma) equilibrated with buffer +T/G. The resin was then poured onto a column. After extensive washing with buffers +T/G and -T/G5 (buffer +T/G minus Triton and glycerol plus 5 mM imidazole), EcMETAP was eluted with buffer -T/G60, containing 60 mM imidazole. EDTA was added immediately to a concentration of 5 mM at the column exit. The protein was then dialysed against three changes of buffer (25 mM HEPES pH 7.5, 150 mM KCl and 15 mM methionine) at 48C. The C-terminal His tag was removed by incubating the protein with biotinylated thrombin (Novagen, 0.25 U/mg) at 158C for 18 -20 h.
The biotinylated thrombin was eliminated by treatment with excess streptavidin agarose. Capture of residual uncleaved His-tagged protein was performed by a second Nickel affinity chromatography. The flowthrough was concentrated and loaded onto a HiLoad 16/60 Superdex-75 gel filtration column (GE Healthcare) equilibrated with buffer (25 mM HEPES pH 7.5, 150 mM KCl and 15 mM methionine). The main peak was pooled, concentrated and aliquoted for storage at 2808C. The purity of the purified apo-enzyme was assessed by capillary electrophoresis (Experion, Bio-Rad) as ≥95%. The molecular mass of purified apo-METAP was 29634.27 Da, in good accordance with the theoretical value. Prior to kinetic assays, the apo-protein was washed free of methionine anaerobically by dialysing against chelexed activity buffer (25 mM HEPES pH 7.5 and 150 mM KCl) and refrozen until use. Goemaere et al.
Enzymatic assays
PDF activity was measured at 378C, essentially as previously described. 35 For determination of kinetic parameters related to Act and other inhibitors, the reaction mixture contained 750 mM of NiCl 2 . METAP enzyme kinetics were measured at 308C on a 96-well UV-star microplate (Greiner) using a microplate spectrophotometer (Powerwave XS, Biotek). METAP activity was monitored spectrophotometrically by quantifying the release of methionine from MetGlyMetMet (MGMM) substrate at 308C using a coupled assay using L-amino acid oxidase (AAO) and horseradish peroxidase (HRP) as outlined elsewhere. 36 Oxidation of released methionine by AAO generates hydrogen peroxide, which is used by HRP to oxidize a co-substrate, o-dianisidine. A microplate reader measured oxidation of o-dianisidine continuously at 440 nm. A typical inhibition assay was performed in a total volume of 200 mL containing 25 mM HEPES pH 7.5, 150 mM KCl, 0.4 mM enzyme, 0.2 mM CoCl 2 , 6 U of HRP, 0.1 U of AAO, 0.1 mg/mL o-dianisidine, 1.5 mM MGMM, inhibitor at different concentrations and 1% DMSO. The initial rates were measured over the first 3 min of incubation and corrected with the background rate determined in the absence of enzyme. The IC 50 values were calculated by non-linear regression analysis of the normalized activity versus log(inhibitor concentration) using GraphPad Prism software.
NMR experiments
E. coli PDF protein was expressed and purified as previously described. 37 All spectra were recorded at 2988K on a Bruker Advance 600 MHz spectrometer equipped with a TCI 5 mm cryoprobe. The NMR samples were prepared in 20 mM phosphate buffer, pH 7.5, at a final concentration of 10 mM for the E. coli PDF and 200 mM for each tested compound. In all mixtures a 1 : 1 molar ratio of the compounds was used.
2 H 2 O was added to the solution (10% final concentration) for the lock signal.
We used the 1D WaterLOGSY sequence previously described by Dalvit et al. 38, 39 Selective water excitation was performed using an inversion Gaussian pulse of 25 ms and two sine-shaped pulsed field gradients along the z-axis of 1 ms length applied with a power of 5 G/cm. The data were collected with a spectral width of 8390 Hz, with an acquisition time of 0.25 s (4096 points) and a relaxation delay of 3 s. The data were zero-filled to 8192 points and multiplied by a squared sine function prior to Fourier transformation. To phase the WaterLOGSY spectrum, we used an internal reference composed of imidazole and/or a-methyl glycoside because neither of these compounds interacts with PDF.
Results
In vitro activity of new PDFIs
Act was used as the standard to characterize the antibacterial activities of the newly produced PDFIs. In vitro activities against EcPDF and EcMETAP are listed in Table 2 . The inhibitory activities of the new oxadiazole hydroxamic acids against EcPDF were found in the nanomolar range, with AT002 being the most active after Act (Table 2 ). In the set, the order of activity against purified Ni-EcPDF was Act. AT002 .AB47 .AT008 .. SMP289 (Table 2) . All PDFIs were also tested for their ability to inhibit Co-EcMETAP. None of them was active except SMP289, which displayed the same order of inhibitory activity as previously reported for other hydroxamic acids. 13, 14 Accordingly, SMP289 appeared to be a weak inhibitor of both EcMETAP and EcPDF with relatively poor activity against the latter (IC 50 312 nM) compared with the other active molecules. A023, a diketo compound, did not inhibit EcPDF and was only poorly active against EcMETAP. of the Act -PDF complex showed that Act binds to the active site of E. coli PDF. The dissociation constant for PDF is in the low nanomolar range. 7, 32 Consequently, WaterLOGSY signals of Act in the presence of PDF are null. The same results were obtained for compounds AT002 and AT008 in the presence of PDF (Table 3) . We further investigated the binding of these two compounds to PDF by recording WaterLOGSY experiments on mixtures containing Act and PDF, and either AT002 or AT008 [ Table 3 and Figure S1 (available as Supplementary data at JAC Online)]. Interestingly, AT002 and AT008 showed negative signals in these conditions, demonstrating that they can no longer interact with PDF when Act is bound at the PDF active site. Indeed, being less potent inhibitors (Table 2) , they are pushed out of the active site by Act unless the conformational change induced by Act or a slow off-rate constant prevents AT008 or AT002 binding. 8 The WaterLOGSY signals of SMP289 were positive, in agreement with its lower affinity for PDF. 32 In the presence of Act, SMP289 exhibited positive WaterLOGSY signals, showing it can still interact with the PDF protein while Act remains tightly bound to the PDF metal active site (null signal). Identical results were obtained whatever the order of addition of the compounds: SMP289 to the mixture of Act and PDF or Act to the mixture of SMP289 and PDF. This suggested that SMP289 and Act binding sites do not overlap and might be synergistic in The signals of SMP289 were always positive and those of AT008 and AT002 became positive as well, showing that the binding of AT002 and AT008 is weaker as a result of competition with SMP289 for the binding site. These experiments show that the binding of SMP289 to PDF lowers the affinity of AT002 and AT008 and suggest that SMP289 and AT002/008 binding sites could overlap (at least partially). Table 4 shows the results obtained in various strains in the absence or presence of various subinhibitory concentrations of the polymyxin nonapeptide PMBN, which is known to increase membrane permeability. 27, 28 It has been demonstrated that only the AcrAB-TolC efflux pump is expressed in AG100 and absent in AG100A. 28, 44 In the absence of membrane permeabilizers, the most efficient molecule was still Act and only against the AG100A strain (Table 4) , and a strong increase in activity was observed in the presence of PMBN, as previously reported particularly with Act and SMP289. 28 These results indicate that, in E. coli cells devoid of an AcrAB efflux pump, the more active compounds were Act .SMP289.AB47 ≈ AT002≈ AT008. Regarding the resistant E. aerogenes isolates devoid of AcrA or TolC efflux components, the activity ranking was very similar: Act . SMP289.AB47 .AT002.AT008. A023 did not exhibit any activity at the concentrations used (up to 128 mg/L).
Activity of new PDFI molecules and membrane permeability
Combination of new PDFI molecules for antibacterial activity in E. coli and E. aerogenes strains
Regarding the level of bacterial susceptibility, we assayed combinations of molecules to evaluate a possible cooperative effect in clinical resistant isolates. The term 'adjuvant' was employed for the molecule used at a fixed concentration (1/5 or 1/10 of the previously determined MIC under the same conditions, without or with PMBN) in the assay carried out to determine the activity of a studied molecule at various concentrations. PMBN played an important role in the efficiencies of combinations. In the absence of a membrane permeabilizer we observed no modification (increase) of susceptibility, suggesting that the adjuvant must penetrate the bacterial wall along with the tested molecule, as previously demonstrated for PDFIs alone. 28 To analyse the possible complementation, the E. coli strain AG100 and its acrAB2 derivative (AG100A) were used. Various combinations were assayed and the results are presented in Table 5 .
A023, which presented no antibacterial activity, was used as the internal control. No modification was observed by adding any adjuvant molecule at 1/5 of the respective MIC. It is interesting to note that Act activity was significantly increased in AG100A in the absence of PMBN, while a smaller effect was observed in the presence of the permeabilizer. Moreover, we also noted a significant effect on susceptibility with the pairs Act+ SMP289 (1/5 MIC) or SMP289+ Act (1/5 MIC), and SMP289+ AT002 (1/5 MIC) ( Table 5 ). These molecule pairs, for which the gains were significant, represented the most active combinations.
A more precise study was carried out using E. aerogenes strains focusing on Act, SMP289 and AT002 as single molecules or in combination (Figure 1) . Interestingly, in E. aerogenes strains a prominent increase in single-molecule susceptibility was obtained with a tolC2 strain (Ea298), although no modification of susceptibility was observed with the parental isolate Ea289, which overexpresses AcrAB-TolC efflux pumps. 45 An intermediate effect was observed with Ea294, the isogenic strain in which the AcrA efflux component is deleted. Among the combinations of molecules, the most effective was Act+ SMP289, for which we observed high susceptibility on acrAB2 and tolC2 derivative strains [ Table 5 , Figure 1 and Table S1 (available as Supplementary data at JAC Online)]. The MIC for Act against Ea294 Ea289, wild-type strain, efflux+; Ea294, acrAB2 derivative of Ea289; Ea298, tolC2 derivative of Ea289; AG100, wild type; AG100A, acrAB2 derivative. ND, not determined.
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(deleted of AcrAB) was 0.5 mg/L when used in combination with PMBN + SMP289 compared with 4 mg/L when used with PMBN alone. It is interesting to note that there was also a small effect with the pair SMP289 +AT002. By contrast, no variation was observed in combinations with A023 (used at the same concentration), which showed no significant effect in a direct assay (Table 5 and Table S1 ). Regarding the other tested pairs, we also noted an increase in SMP289 activity in the presence of AT002, AT008 or Act, the best combination being SMP289/Act. This effect was mainly detected in tolC2 and acrAB2 strains. These results suggest that the addition of an adjuvant molecule results in an increase in the antibacterial activity of the parent molecule, Act or SMP289.
Discussion
Faced with the continuous increase in multidrug resistance of bacterial pathogens, a possible rational alternative is to develop new strategies for improving the intracellular concentrations of antibacterial agents. We recently demonstrated that the activity of different PDFIs was dependent on increasing the intracellular concentrations of antibacterials. 28 Similarly to other antibacterial agents, the intracellular concentration depends on the activity of efflux pumps. 24 In E. coli AG100A in the presence of a permeabilizer (Table 5) , the association of Act with SMP289 (1/5 MIC) led to a 4-fold decrease in the MIC value. A similar result was observed with the combinations AB47 + Act (1/5 MIC) versus AB47 alone, Active combination of PDF-METAP inhibitors SMP289+ Act or AT002 (1/5 MIC) versus SMP289 alone and AT002+ AT008 (1/5 MIC) versus AT002 alone. However, MIC values ,1 mg/L were reached only with the pairs including Act and SMP289 as the parent molecule or adjuvant, these molecules being the best lead compounds against AG100A in the presence of PMBN. This suggests strong cooperativity between the two molecules. Several non-exclusive hypotheses can be proposed to explain the effect of the combinations. The first of these is saturation of the AcrB efflux process by competition occurring inside the pump channel, as previously reported for several other antibiotic molecules that are substrates of efflux pumps or decoy molecules. 27 Consequently, an increase in intracellular PDFI concentration for the same external amount results in a decrease in MIC. In AG100, in the presence of PMBN, the activity of Act was weakly improved in the presence of AT008, SMP289 or AB47, suggesting that the efflux pump could be saturated in the presence of molecules targeting PDF less efficiently than Act. However, when the bacterial efflux component AcrAB or TolC was absent due to specific deletions, a greater effect was observed, suggesting that this hypothesis alone does not provide a full explanation. Indeed, when tested alone, deletion of the efflux pump components allowed AT008 and AT002 to reach their target inside the cell.
The second hypothesis focuses on the activity of enzymes involved in the N-formyl methionine excision process. 3 Act is a potent inhibitor of E. coli PDF, and there may be a synergistic effect of Act with (for instance) AT008, yielding a quasi-complete blockage of PDF and thus of the maturation of nascent polypeptides. SMP289 is a remarkable molecule, being a much less effective inhibitor of PDF than Act or AT002 or AT008, but the only molecule of the series able to inhibit the E. coli Co-METAP. Moreover, we observed an increase in the activity of SMP289 in AG100A in the presence of AT008, AT002 or Act while no effect was obtained with A023 as control. In the absence of the AcrAB efflux pump, the effect of these combinations, and especially the Act/SMP289 association, suggests a collaborative/sequential inhibition of two enzymes, PDF and METAP, involved in the maturation of newly synthesized polypeptide chains. 3 A similar hypothesis can explain the variation in susceptibility obtained in E. aerogenes strains 294 and 298. Interestingly, the combination using SMP289 (or Act) as adjuvant molecule of Act (or SMP289) was more potent in Ea298 than in AG100A, and even better than the usual antibiotics alone [0.125 mg/L for the combination Act +SMP289 versus 1 mg/L for Act alone and 0.5 mg/L for SMP289+ Act versus 8 mg/L for SMP289 alone ( Figure 1 and Table S1 ) and 16 mg/L for chloramphenicol or 32 mg/L for norfloxacin (Table 4) ].
Another interesting effect of SMP289 is demonstrated by the NMR experiments. It can be concluded that SMP289 is able to perturb the binding of AT002 and AT008 but not the tight binding of Act to PDF. Regarding AT002, AT008 and Act and the X-ray structures of any Act -PDF complex available in the literature, 42 it is obvious that steric hindrance in the close proximity of the PDF metal active site precludes concomitant binding at the same site of Act and another inhibitor, such as an AT Goemaere et al.
compound or SMP289. However, NMR experiments showed that SMP289 interacts more weakly with PDF and in a different manner compared with AT002 and AT008. Simultaneous binding of SMP289 and Act is tolerated, but the two binding sites do not seem to overlap. In this context, we cannot exclude the possibility that SMP289 binds to an alternative binding pocket of PDFs that is distinct from the active site. This pocket was initially revealed by docking studies of the E. coli enzyme. 46 Its existence was confirmed recently with the highresolution structure of PDF in complex with another PDF inhibitor also featuring an aromatic side chain and a hydroxamic moiety. 8 Another non-exclusive explanation might be that SMP289 inhibits METAP (IC 50 5.7 mM) while Act specifically inhibits most but not all intracellular PDFs (IC 50 5.3 nM). This would result in a more complete block of N-terminal methionine excision through conjoint inhibition of the two successive enzymes involved in the protein pathway in the bacterium. The three other PDF inhibitors discussed in this work did not exhibit noticeable activity against METAP.
To conclude, this is the first time that a combination of different inhibitors that target either PDF, or PDF and METAP, has been reported. Under conditions favouring easier diffusion of active molecules through the outer membrane, we markedly improved the antibacterial activity of these molecules and reached an important susceptibility level compared with the use of a single inhibitor. These data are of importance because the combination of molecules that target two associated metabolic steps resulted in a cooperative effect that improved their antibacterial spectra.
